CHMP gives Pradaxa new contraindication, limits long-term use of calcitonin medicines
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has added Sanofi's antiarrythmic drug Multaq (dronedarone) to the list of contraindicated medicines associated with Boehringer Ingelheim’s anti-coagulant Pradaxa (dabigatran etexilate). Systemic ketoconazole, cyclosporine, itraconazole and tacrolimus are also contraindicated.